[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Affimed N.V. (AFMD)

Affimed N.V. (AFMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,922
  • Shares Outstanding, K 16,100
  • Annual Sales, $ 8,960 K
  • Annual Income, $ -114,660 K
  • EBIT $ -76 M
  • EBITDA $ -74 M
  • 60-Month Beta 2.07
  • Price/Sales 2.86
  • Price/Cash Flow N/A
  • Price/Book 0.15
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.50
  • Most Recent Earnings $-1.03 on 11/14/24
  • Next Earnings Date 06/11/25
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate $-0.52
  • Number of Estimates 2
  • High Estimate $-0.39
  • Low Estimate $-0.65
  • Prior Year $-1.38
  • Growth Rate Est. (year over year) +62.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0701 +158.92%
on 05/15/25
1.1300 -83.94%
on 05/01/25
-0.5520 (-75.26%)
since 04/17/25
3-Month
0.0701 +158.92%
on 05/15/25
1.1300 -83.94%
on 05/01/25
-0.8785 (-82.88%)
since 02/19/25
52-Week
0.0701 +158.92%
on 05/15/25
8.9500 -97.97%
on 06/12/24
-5.0685 (-96.54%)
since 05/17/24

Most Recent Stories

More News
Affimed Announces Receipt of Nasdaq Delisting Notice

MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients...

AFMD : 0.1815 (-34.95%)
Affimed Announces Filing for the Opening of Insolvency Proceedings

MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients...

AFMD : 0.1815 (-34.95%)
Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly demonstrates that higher...

AFMD : 0.1815 (-34.95%)
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting

MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company...

AFMD : 0.1815 (-34.95%)
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients...

AFMD : 0.1815 (-34.95%)
Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting

MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients...

AFMD : 0.1815 (-34.95%)
Affimed N.V. Reports Promising 40% Complete Remission Rate for AFM28 in Heavily Pretreated R/R AML Patients

AFM28 shows 40% complete remission rate in R/R AML patients with manageable safety profile in Phase 1 trial.Quiver AI SummaryAffimed N.V. announced promising results for its bispecific innate cell engager,...

AFMD : 0.1815 (-34.95%)
Affimed N.V. Reports Encouraging Efficacy of Acimtamig Combined with AlloNK® in R/R Classical Hodgkin Lymphoma at ASH Annual Meeting

Acimtamig with AlloNK® shows 86% response rate in relapsed/refractory classical Hodgkin lymphoma, with manageable safety.Quiver AI SummaryAffimed N.V. announced promising results from a study combining...

AFMD : 0.1815 (-34.95%)
AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy

Affimed N.V. AFMD announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its pipeline candidate, acimtamig (AFM13).The regulatory body granted the RMAT designation...

AFMD : 0.1815 (-34.95%)
CSTL : 34.02 (+3.00%)
SPRO : 1.2000 (-1.64%)
ARTV : 11.28 (-0.18%)
Affimed Receives FDA RMAT Designation for Acimtamig and Artiva’s AlloNK® in Relapsed/Refractory Hodgkin Lymphoma Treatment

Affimed's acimtamig and Artiva's AlloNK® receive FDA RMAT designation for treating relapsed/refractory Hodgkin Lymphoma based on promising early data.Quiver AI SummaryAffimed N.V. announced that the U.S....

AFMD : 0.1815 (-34.95%)

Business Summary

Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V.,...

See More

Key Turning Points

3rd Resistance Point 0.2865
2nd Resistance Point 0.2618
1st Resistance Point 0.2216
Last Price 0.1815
1st Support Level 0.1567
2nd Support Level 0.1320
3rd Support Level 0.0918

See More

52-Week High 8.9500
Fibonacci 61.8% 5.5579
Fibonacci 50% 4.5100
Fibonacci 38.2% 3.4622
Last Price 0.1815
52-Week Low 0.0701

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.